
Thomas J Moore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7657471/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Author Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. Neurology, 2022, 98, 49-50.	1.1	0
2	Safety and effectiveness of <scp>NMDA</scp> receptor antagonists for depression: A multidisciplinary review. Pharmacotherapy, 2022, 42, 567-579.	2.6	8
3	Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products. JAMA Internal Medicine, 2021, 181, 52.	5.1	25
4	Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin. Psychiatric Services, 2021, 72, 77-80.	2.0	2
5	Changes in medical use of central nervous system stimulants among US adults, 2013 and 2018: a cross-sectional study. BMJ Open, 2021, 11, e048528.	1.9	5
6	Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. Neurology, 2021, 97, e1266-e1275.	1.1	29
7	Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication. JAMA Oncology, 2021, 7, 1720-1721.	7.1	4
8	Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018. Annals of Internal Medicine, 2020, 173, 956-963.	3.9	2
9	Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study. BMJ Open, 2020, 10, e038863.	1.9	38
10	Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis. BMJ Open, 2020, 10, e039978.	1.9	42
11	US Food and Drug Administration Safety Advisories and Reporting to theÂAdverse Event Reporting System (FAERS). Pharmaceutical Medicine, 2020, 34, 135-140.	1.9	9
12	Estimated costs of pivotal trials for U.S. Food and Drug Administration–approved cancer drugs, 2015–2017. Clinical Trials, 2020, 17, 119-125.	1.6	12
13	Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015–2016. Clinical Trials, 2019, 16, 329-333.	1.6	12
14	Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016. JAMA Internal Medicine, 2018, 178, 1451.	5.1	219
15	Assessment of Patterns of Potentially Unsafe Use of Zolpidem. JAMA Internal Medicine, 2018, 178, 1275.	5.1	18
16	Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and Race. JAMA Internal Medicine, 2017, 177, 274.	5.1	163
17	The Fate of FDA Postapproval Studies. New England Journal of Medicine, 2017, 377, 1114-1117.	27.0	64
18	The Harms of Antipsychotic Drugs: Evidence from Key Studies. Drug Safety, 2017, 40, 3-14.	3.2	7

2

Thomas J Moore

#	Article	IF	CITATIONS
19	Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014. Pharmacoepidemiology and Drug Safety, 2016, 25, 713-718.	1.9	33
20	Electronic Health Data for Postmarket Surveillance: A Vision Not Realized. Drug Safety, 2015, 38, 601-610.	3.2	36
21	Antidepressants increase, rather than decrease, risk of suicidal behaviours in younger patients. BMJ, The, 2014, 349, g5626-g5626.	6.0	2
22	Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs. JAMA Internal Medicine, 2014, 174, 1930.	5.1	246
23	Dabigatran, bleeding, and the regulators. BMJ, The, 2014, 349, g4517-g4517.	6.0	70
24	Underreporting of Hemorrhagic and Thrombotic Complications of Pharmaceuticals to the U.S. Food and Drug Administration: Empirical Findings for Warfarin, Clopidogrel, Ticlopidine, and Thalidomide from the Southern Network on Adverse Reactions (SONAR). Seminars in Thrombosis and Hemostasis, 2012, 38, 905-907.	2.7	28
25	New Drug: Caution Indicated. Archives of Internal Medicine, 2012, 172, 1681.	3.8	1
26	The FDA and New Safety Warnings. Archives of Internal Medicine, 2012, 172, 78.	3.8	43
27	Suicidal Behavior and Depression in Smoking Cessation Treatments. PLoS ONE, 2011, 6, e27016.	2.5	128
28	Prescription Drugs Associated with Reports of Violence Towards Others. PLoS ONE, 2010, 5, e15337.	2.5	75
29	Thoughts and Acts of Aggression/Violence Toward Others Reported in Association with Varenicline. Annals of Pharmacotherapy, 2010, 44, 1389-1394.	1.9	29
30	latrogenic Effects of COX-2 Inhibitors in the US Population. Drug Safety, 2009, 32, 335-343.	3.2	24
31	Risk of psychiatric side effects with varenicline. BMJ: British Medical Journal, 2009, 339, b4964-b4964.	2.3	23
32	Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration. PLoS Medicine, 2008, 5, e45.	8.4	1,935
33	Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005. Archives of Internal Medicine, 2007, 167, 1752.	3.8	376
34	Reported medication errors associated with methotrexate. American Journal of Health-System Pharmacy, 2004, 61, 1380-1384.	1.0	55
35	Reported Adverse Event Cases of Methemoglobinemia Associated With Benzocaine Products. Archives of Internal Medicine, 2004, 164, 1192.	3.8	97
36	Reported Adverse Drug Events in Infants and Children Under 2 Years of Age. Pediatrics, 2002, 110, e53-e53.	2.1	111

Thomas J Moore

#	Article	IF	CITATIONS
37	Effects of Diet and Sodium Intake on Blood Pressure: Subgroup Analysis of the DASH-Sodium Trial. Annals of Internal Medicine, 2001, 135, 1019.	3.9	475
38	Effect of Dietary Patterns on Ambulatory Blood Pressure. Hypertension, 1999, 34, 472-477.	2.7	124
39	Time for Action on Drug Safety—Reply. JAMA - Journal of the American Medical Association, 1999, 281, 320.	7.4	1